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Thrombospondin-1 (TSP-1) is a multifunctional matrix protein with antitumor activities due in part to 
its ability to inhibit angiogenesis, which in turn contributes to determine the fate of many tumours. 
Previous studies have shown that TSP-1 expression supports normal kidney angiostasis, and decreased 
TSP-1 levels contribute to the angiogenic phenotype of renal cell carcinomas (RCC). The loss of the von 
Hippel-Lindau tumour suppressor gene (VHL) in these tumours favours stabilization of the Hypoxia 
Inducible Factors (HIF), which in turn contribute to adapt tumour cells to hostile environments 
promoting tumour progression. However, HIF-independent regulation of certain genes might also 
be involved. We have previously shown that TSP-1 is regulated in hypoxia in clear cell RCC (ccRCC) in 
a HIF-independent manner; however, the effect of VHL protein (pVHL) on TSP-1 expression has not 
been evaluated. Our results proved that pVHL loss or mutation in its alpha or beta domain significantly 
decreased TSP-1 levels in ccRCC in a HIF-independent manner. Furthermore, this regulation proved to 
be important for ccRCC cells behaviour showing that decreased TSP-1 levels rendered ccRCC cells more 
migratory. This data substantiates a unique regulation pattern for TSP-1 in a pVHL-dependent manner, 
which may be relevant in the aggressiveness of ccRCC.
Dysregulation of the von Hippel-Lindau (VHL) gene is closely associated with clear cell renal cell carcinoma 
(ccRCC), being this one of the most common features in patients with the Von Hippel-Lindau disease1. This 
disease is an autosomal dominant hereditary cancer syndrome caused by germ line mutations or deletions in 
the VHL tumour suppressor gene2. Several pieces of evidence have implicated this gene as a gatekeeper gene 
in the pathogenesis of RCC, these including VHL gene mutations in most primary sporadic renal cell carci-
nomas (RCCs) and the development of renal cysts in Vhl conditional knockout mice3–7. VHL protein (pVHL) 
is the substrate recognition component of a multi-subunit complex with E3 ubiquitin ligase activity that also 
comprise elongin B, elongin C, Cul2 and RBx18,9. This protein complex is also a central component in the 
oxygen-sensing machinery involved in the proteasome-mediated degradation of the hypoxia-inducible factor 
(HIF)-α10,11. Therefore, VHL loss or certain mutations in this tumour suppressor gene lead to the stabilization 
of HIF in normoxia12 which in turn promotes the transcription of HIF target genes, these including angiogenic 
factors like vascular endothelial growth factor A (VEGF A)13. Although the high expression of VEGF may pro-
vide an explanation for the high vascularization of these pVHL-negative tumours, this alone is not sufficient 
to promote the growth of RCC xenografts and additional events may be involved. In this respect, other pVHL 
HIF-independent functions have been shown to be required and help to explain why loss of pVHL leads to renal 
cancer14. In particular, it is interesting to highlight the pVHL-mediated regulation of intercellular junctions and 
extracellular matrix homeostasis and its contribution to the growth and progression of RCC15–17. In addition, 
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negative regulation of anti-angiogenic factors may also contribute to promote growth of RCC xenografts; how-
ever, their role in the progression of these carcinomas has been largely ignored. One of these factors is the mul-
timeric and multifunctional matricellular protein thrombospondin-1 (TSP-1). This protein belongs to a family of 
five extracellular matrix proteins with similar structures18,19 and is the first identified angiogenesis inhibitor20,21. 
Furthermore, its expression is critical for the maintenance of the anti-angiogenic microenvironment in a variety 
of experimental tumours and metastases, such as breast, brain, colon, bladder and skin22–27.
TSP-1 modulates cell behaviour by altering cell adhesion, motility, proliferation, survival and growth of many 
cell types in vitro, gene expression, and differentiation28,29. Additionally, TSP-1 expression is frequently lost during 
malignant transformation due to regulation of its expression by oncogenes, tumour suppressor genes and hyper-
methylation27,30,31. These properties have attracted interest in this matricellular protein as a potential regulator of 
tumour growth and metastasis.
Our results demonstrate that pVHL expression positively regulates TSP-1 protein levels, and this regulation 
is not at the transcriptional level since we did not observe regulation of TSP-1 mRNA levels. In addition, we also 
demonstrate that TSP-1 regulation by pVHL is a HIFα−independent event. Finally, we analysed the relevance 
of TSP-1 regulation in the aggressiveness of these carcinoma cells and found that decreased TSP-1 expression 
rendered ccRCC cells more migratory.
Results
TSP-1 levels are diminished in ccRCC cells lacking pVHL. As a tumour suppressor protein, pVHL 
plays an important role in the regulation of extracellular matrix homeostasis, an important event in the growth 
and progression of renal cell carcinomas17,32–36. Considering this, we asked whether pVHL could also regulate 
TSP-1. We analysed TSP-1 mRNA and protein expression levels in several ccRCC cell lines (786-O, RCC4 and 
RCC10). TSP-1 mRNA levels did not differ significantly between pVHL positive and negative clones, although 
VEGF mRNA showed the expected up-regulation of gene expression in the absence of pVHL (Fig. 1a). In con-
trast, TSP-1 protein levels were significantly decreased in total cell lysates from the different ccRCC parental cell 
lines (786-O, RCC4 and RCC10) compared to the clones stably expressing pVHL (Fig. 1b). Given that TSP-1 is a 
glycoprotein that is actively secreted into the medium, we also analysed whether decreased protein levels found 
in our total cell lysates were due to an increased rate of TSP-1 secretion. TSP-1 levels in conditioned media were 
correspondingly decreased in cells lacking pVHL compared to the respective pVHL positive cells (Fig. 1b). Thus, 
total TSP-1 protein levels are decreased in cell lines lacking pVHL. In order to confirm that the decrease of TSP-1 
levels was due to the lack of pVHL and not to secondary alterations occurring during passage, we knocked down 
VHL by siRNA, and the degree of silencing was quantified by western blot. VHL interference led to a marked 
decrease of TSP-1 protein levels, similar to those in pVHL negative cells (Fig. 1c).
pVHL mutations in its alpha or beta domain decrease TSP-1 levels. In order to gain further proof 
of the role of pVHL in TSP-1 regulation we also used 786-O sublines stably transfected with well-characterized 
naturally occurring mutant forms of pVHL in its alpha (L188V) or its beta domain (Y112H). Our results indi-
cated that TSP-1 protein levels were decreased in both mutants to levels resembling those in pVHL negative 
cells (Fig. 2a). Additionally, we generated different pVHL mutations that produced other truncated forms in 
its alpha domain (1–161, 1–164 and 1–171) and tested for VHL transcripts expression (Fig. 2b, upper panel). 
TSP-1 levels were similarly decrease with all these mutants compared with the wild type pVHL (Fig. 2b, lower 
panels). Taken together these data demonstrate that in ccRCC cell lines TSP-1 protein levels are regulated in a 
pVHL-dependent manner and, most importantly, both, its alpha and beta domains are critical for the regula-
tion of TSP-1 protein.
TSP-1 regulation in ccRCC cell lines is not mediated by its interaction with pVHL. It has been 
previously shown that pVHL binds to proteins increasing their stability, without causing variations in their 
mRNA37,38. Taking this into account and the results with TSP-1 shown above, we considered analysing whether 
the decrease in protein in ccRCC lines could be related to the lack of interaction between pVHL and TSP-1. To 
this aim, we carried out immunoprecipitation experiments. After analysing the results by western blotting, no 
bands corresponding to TSP-1 were observed in the pVHL immunoprecipitates. Likewise, we did not observe 
bands corresponding to pVHL when precipitating the lysates with anti-TSP-1 antibodies (Fig. 3). Therefore, these 
results indicate that the regulation of TSP-1 in ccRCC does not depend on its direct interaction with pVHL.
TSP-1 decrease in pVHL negative cells is HIF independent. VHL best-known function is the regu-
lation of HIF-α proteolytic degradation12,39. Given that in the absence of pVHL these factors are stabilized, we 
asked whether TSP-1 decreased protein levels in pVHL negative cells were a HIF-mediated effect. To this aim we 
infected wild-type pVHL-transfected 786-O cells, which only express HIF-2α, with a retrovirus encoding the 
empty vector (pBabe), a constitutively active form of HIF-2α (HIF-2αpp), or with a mutant lacking transcrip-
tional activity (HIF-2αbHLH)16. Western blots quantification from total cell lysates showed no modification on 
TSP-1 protein levels in cells infected with the constitutively active form of HIF2α (Fig. 4a) indicating that this 
factor was not involved in TSP-1 protein decrease in the absence of pVHL. To further confirm these results we 
knocked down the expression of HIF1α or HIF2α in the RCC4 cell line, using specific siRNAs. Interestingly, 
when we knocked down them in both pVHL positive and negative cells we only observed a slight decrease but 
never a TSP-1 protein recovery (Fig. 4b). Additionally, HIF-independent regulation of TSP-1 in ccRCC cells was 
also confirmed in cells expressing the L188V or the Y112H mutant forms of pVHL, the first reported to regulate 
HIF normally although it is defective in promoting the assembly of fibronectin extracellular matrix40,41. Our 
results demonstrated that despite HIF-2α levels were low in normoxia in this mutant cells, TSP-1 levels were 
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similarly decreased in normoxia or hypoxia in both, the pVHL L188V and Y112H mutants to levels resembling 
those in pVHL negative cells (Fig. 4c). Taken together these data demonstrate that TSP-1 decrease in ccRCC 
pVHL negative cell lines is independent of HIF.
Figure 1. TSP-1 levels are diminished in ccRCC cells lacking pVHL. (a) Quantitative RT–PCR analysis was 
performed to determine TSP-1 and VEGF mRNA expression levels from pVHL-positive (pRV-VHL) and 
negative (pRV) 786-O, RCC4 and RCC10 cell lines. mRNA levels are expressed as fold change over pVHL-
positive cells, normalized with HPRT as housekeeping gene and presented as mean ± SEM, n = 4–5. Statistical 
comparisons between different pairs were made using one-sample t-test (n.s. = non-significant, *P < 0.05). 
(b) Protein levels from total cell lysates (TL) and conditioned media (CM) from pVHL-positive and negative 
cells were determined by western blot probed against TSP-1 and α-tubulin as loading control. Representative 
images and band quantifications by densitometry are shown and presented as mean ± SEM, n = 5–6. Statistical 
comparisons between different pairs were made using one-sample t-test (**P < 0.01, ***P < 0.005). (c) 
pVHL-positive RCC4 cells were transiently transfected with control (scr) or pVHL-specific siRNA (siVHL). 
Protein levels from total cell lysates from non-transfected (–), scr or pVHL-specific (siVHL) siRNA-transfected 
pVHL-positive RCC4 cells were determined by western blot probed against TSP-1, pVHL and α-tubulin as 
loading control. Representative images and band quantifications by densitometry are shown and presented as 
mean ± SEM, n = 5. Statistical comparisons between different conditions were made using one-way ANOVA 
test followed by linear trend post-hoc test (#P-trend < 0.05). Full-length blots are presented in Supplementary 
Fig. S2.
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Intercellular junction integrity in pVHL-negative RCC cells is dependent on TSP-1 levels. Our 
previously published results demonstrate a defective distribution of intercellular junctions in ccRCC, which are 
restored by the expression of pVHL. Furthermore, these effects are independent on pVHL-mediated regulation 
of HIF16. Hence, we asked whether the decreased levels of TSP-1 in these cells were involved in maintaining 
Figure 2. pVHL mutations in its alpha or beta domain decrease TSP-1 levels. (a) Protein levels from pVHL-
positive, pVHL-negative, and pVHL-mutant-expressing (L188V or Y112H) 786-O cells were determined 
by western blot probed against TSP-1 and α-tubulin as loading control. Representative images and band 
quantifications by densitometry are shown and presented as mean ± SEM, n = 3. Statistical comparisons 
between different conditions were made using one-way ANOVA test followed by Bonferroni’s post-hoc test 
(**P < 0.01, ***P < 0.005). (b) Quantitative RT–PCR analysis was performed to determine VHL mRNA 
expression from pVHL-positive, pVHL-negative and truncated pVHL-mutant-expressing (1–161, 1–164 or 
1–171) RCC4 cells. mRNA levels are expressed as fold change over pVHL-negative cells, normalized with HPRT 
as housekeeping gene and presented as mean ± SEM, n = 3 (upper panel). Protein levels from pVHL-positive, 
pVHL-negative and truncated pVHL-mutant-expressing (1–161, 1–164 or 1–171) RCC4 cells were determined 
by western blot probed against TSP-1, pVHL and α-tubulin as loading control. Representative images and 
band quantifications by densitometry are shown and presented as mean ± SEM, n = 5 (lower panels). Statistical 
comparisons between different conditions were made using one-way ANOVA test followed by Bonferroni’s 
post-hoc test (n.s. = non-significant, *P < 0.05, **P < 0.01, ***P < 0.005). Full-length blots are presented in 
Supplementary Fig. S2.
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intercellular adhesion in ccRCC lines. To analyse this we knocked down this protein in pVHL expressing 786-O 
and RCC4 cell lines (Fig. 5a) and performed double immunofluorescence staining and microscopy analysis of 
the junctional proteins β-catenin and zonulin (ZO)-1. Our results showed that pVHL expressing cells with TSP-1 
decreased levels displayed an irregular immunofluorescent staining pattern of β-catenin and ZO-1 distribution, 
thus indicating that pVHL-dependent restoration of normal intercellular junctions was affected by the levels of 
TSP-1 in these cells (Fig. 5b). These results suggested that both phenomena, pVHL loss and decreased TSP-1 
levels in ccRCC, might be linked.
TSP-1 expression regulates RCC cell migration and invasion. It has been shown that secretion of 
angiogenic factors stimulates RCC cell migration, although the role of endogenous angiogenic inhibitors such as 
TSP-1 in autocrine regulation of RCC cells remains unexplored. On the other hand, we have previously described 
that hypoxia-mediated suppression of TSP-1 promotes migration in ccRCC42. Considering this, we asked whether 
decreased expression of TSP-1 in the absence of pVHL also contributed to RCC cell motility and invasion. To 
analyse this, we first performed wound healing assays to compare motility between pVHL positive and negative 
cells. Figure 6a shows a decreased motility of pVHL expressing cells after 16 h compared to pVHL negative cells. 
To ascertain whether TSP-1 decrease in pVHL negative cells was involved in cell migration we compared migra-
tion rates in these cells with pVHL expressing ccRCC cells transfected with scramble or a specific TSP-1 siRNA. 
As shown in Fig. 6b, pVHL positive cells transfected with TSP-1 siRNA showed increased motility, evidenced by 
the increased number of cells in the wounded area, compared to cells transfected with a scramble siRNA, whereas 
the migration was similar to that of pVHL negative cells. In addition, the TSP-1 siRNA-transfected cells were also 
analysed for their ability to invade through a type I collagen matrix using a Transwell® insert assay system. As a 
chemoattractant we used medium with 10% FBS or serum-free medium as a negative control. None of the cell 
lines migrated towards the serum-free media control (data not shown). However, when stimulated with serum, 
pVHL positive cells transfected with siRNA to TSP-1 showed a significant increase of cell migration/invasion 
compared to cells transfected with scramble siRNA. Furthermore, this was similar to that of pVHL negative cells 
(Fig. 6c). Taken together these results indicated that the lack of pVHL in ccRCC promotes an increase of cell 
migration through decreasing TSP-1 levels.
Discussion
Renal cell carcinoma is the most common malignant tumour of the adult kidney. Nowadays, advanced renal cell 
carcinoma is commonly treated with VEGF or mammalian target of rapamycin inhibitors43. However, therapies 
targeting VEGF must be cautiously considered44. Therefore, a deeper understanding of the molecular events that 
occur in these tumours will improve the design of more effective therapies. Our studies in different RCC cell 
lines indicated that the absence of the tumour suppressor gene pVHL induced a decrease in the expression of the 
tumour and angiogenesis inhibitor TSP-1. This regulation proved to be important for the RCC cell behaviour and 
correlated with an increased migratory and invasive potential. Interestingly, our previous studies demonstrate 
that stabilization of HIFα in ccRCC is not sufficient to restore neither a differentiated epithelial phenotype nor 
proper intercellular junction assembly16. In this paper, we demonstrate that the integrity of intercellular junctions 
in pVHL-negative RCC cells is dependent on TSP-1 levels. In this respect, previous reports have shown that 
TSP-1 is important in maintaining normal kidney angiostasis and its expression inversely correlates with micro-
vascular density, proliferation and progression in RCC42,45–47; however, none of them have addressed whether the 
lack of pVHL in these tumours affects TSP-1 expression. In this line, Veliceasa et al. found that TSP-1 secretion 
is impaired in RCC compared with normal renal epithelium due to protein misfolding caused by changes in 
calcium uptake46. However, this cannot explain the decreased protein levels in our pVHL negative RCC lines 
Figure 3. TSP-1 regulation in ccRCC cell lines is not mediated by its interaction with pVHL. Total cell lysates 
from pVHL-positive cells were immunoprecipitated (IP) to study the association of pVHL and TSP-1 proteins. 
Immunoprecipitation was carried out with antibodies against pVHL (upper panels) or TSP-1 (lower panels), 
and protein levels were determined afterwards by western blot probed against pVHL and TSP-1. Additional 
lanes showing the signal from the antibodies used in the immunoprecipitation (Ig) and from total lysates (TL), 
are also included in the western blot images. Full-length blots are presented in Supplementary Fig. S2.
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Figure 4. TSP-1 decrease in pVHL-negative cells is HIF-independent. (a) Protein levels from control or 
HIF-2α-mutant-expressing pVHL-positive 786-O cells (empty vector pBabe, HIF-2αPP or HIF-2αbHLH 
mutants) were determined by western blot probed against TSP-1, HIF-2α and α-tubulin as loading control. 
Representative images and band quantifications by densitometry are shown and presented as mean ± SEM, 
n = 3–4. Statistical comparisons between different conditions were made using one-way ANOVA test followed 
by Bonferroni’s post-hoc test (n.s. = non-significant). (b) Protein levels from non-transfected (–), scr, HIF-
1α-specific (siHIF-1α) or HIF-2α-specific (siHIF-2α) siRNA-transfected pVHL-positive and pVHL-negative 
RCC4 cells were determined by western blot probed against TSP-1, HIF-1α and α-tubulin as loading control. 
Representative images and band quantifications by densitometry are shown and presented as mean ± SEM, 
n = 3. Statistical comparisons between different conditions were made using one-way ANOVA test followed 
by Bonferroni’s post-hoc test (n.s. = non-significant). (c) Protein levels from control pVHL-positive, pVHL-
negative, L188V and Y112H pVHL-mutant-expressing 786-O cells cultured under normoxia (Nx, 21% O2) or 
hypoxia (Hp, 1% O2) for 24 hours were determined by western blot probed against TSP-1, HIF-2α, pVHL and 
α-tubulin as loading control. Representative images and band quantifications by densitometry are shown and 
presented as mean ± SEM, n = 3. Statistical comparisons between different conditions were made using one-
way ANOVA test followed by Bonferroni’s post-hoc test (***P < 0.005 with respect to the levels of 786-O cells 
cultured under normoxia). Full-length blots are presented in Supplementary Fig. S2.
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compared to the pVHL expressing ones, since our results showed decreased protein levels in both, total cell lysates 
and secreted protein in cell-conditioned media. Therefore, a different pVHL-dependent mechanism might be 
responsible for the increased levels of TSP-1 in pVHL expressing carcinoma cell lines. Besides the role of pVHL in 
the proteasome-mediated degradation of HIFα12, other pVHL targets such as BIMEL37, p5348 and Jade-138 have 
enhanced stabilization and increased half-life. Although this new pVHL function of increasing protein stability 
could explain the increased TSP-1 levels in pVHL expressing cells, we did not prove pVHL interaction with 
TSP-1 in pull down assays, this indicating that TSP-1 regulation by pVHL must be indirect. In addition, experi-
ments using different inhibitors of protein degradation did not recover TSP-1 levels in pVHL lacking cells (data 
not shown). Causes that may account for the loss of TSP-1 might include the diminished positive regulation by 
tumour suppressor genes like p53, and PTEN among others or an increased negative regulation by oncogenes 
including myc, Ras, and Id149–51. In this respect, pVHL has been shown as a positive regulator of p5348. We found 
decreased p53 mRNA levels in the 786-O cell line, while no significant differences were observed in the RCC4 
cell line (Supplementary Fig. S1a). However, p53 protein levels were significantly decreased in all the analysed 
pVHL negative and in the pVHL mutants L188V and Y112H (Supplementary Fig. S1b). These results support that 
VHL-p53 nexus might be involved in the regulation of TSP-1 in these cells. However, Zubac et al. have demon-
strated no positive correlation between TSP-1 levels and p53 expression in ccRCC45. A plausible explanation 
to this would be that despite p53 levels are higher in pRV-VHL cells, its activity might not be correspondingly 
increased. Interestingly, the analysis of p21, a p53 target gene, in our ccRCC cells proved a wide variability of 
results. In the RCC4 cell line, p21 levels were lower compared to RCC4 cells expressing VHL. Accordingly, the 
Figure 5. Intercellular junction integrity in pVHL-negative RCC cells is dependent on TSP-1 levels. (a) Protein 
levels from non-transfected (−), scr or TSP-1-specific (siTSP-1) siRNA-transfected pVHL-positive and negative 
786-O and RCC4 cells were determined by western blot probed against TSP-1 and α-tubulin as loading control. 
Full-length blots are presented in Supplementary Fig. S2. (b) Immunofluorescence of scr or TSP-1-specific 
(siTSP-1) siRNA-transfected pVHL-positive and negative 786-O and RCC4 cells was used to visualize β-catenin 
(green) and ZO-1 (red) in adherens and tight cell junctions. Representative images from three independent 
experiments are shown.
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levels of p53 were also lower in VHL-deficient cells compared to VHL-expressing RCC4 cells. Conversely, in 
the 786-O cell line the levels of p21 did not always correlated with those of p53 (Supplementary Fig. S1a,b). This 
might be related to the phosphorylation state of p53. Interestingly, we observed a higher molecular weight band in 
p53 blots that is likely to correspond to a phosphorylated form of this protein, especially in 786-O pRV cells and 
Y112H mutant (Supplementary Fig. S1b). Moreover, precisely in these cells the levels of p21 were higher. These 
results are difficult to interpret and may explain why other authors found that p53 regulation in ccRCC cells is 
independent of VHL52. Additionally, to test whether TSP-1 regulation in ccRCC cell lines was due to an increase 
in oncogenes we analysed the levels of myc. However, neither mRNA nor protein myc levels showed a signifi-
cant increase in pRV or VHL-mutant cells (Supplementary Fig. S1a,b). Other mechanisms such as epigenetic 
changes, these including hypermethylation of CpG islands around the transcription start site are also involved in 
Figure 6. TSP-1 expression regulates RCC cell migration and invasion. (a) Non-transfected (–), scr or TSP-1-
specific (siTSP-1) siRNA-transfected pVHL-positive and negative 786-O and RCC4 cells were seeded on 24-well 
plates and experimental wounds were made with a pipette tip across the central line of each well. Cells between 
the scraped edges were counted 16 hours later. Representative phase contrast images are shown. Data from 
cell quantification are presented as mean ± SEM, n = 3. Statistical comparisons between different conditions 
were made using one-way ANOVA test followed by Bonferroni’s post-hoc test (**P < 0.01, ***P < 0.005). (b) 
Transwell® assays were used to analyse cell invasion through collagen matrices to FBS as chemoattractant. Scr 
or TSP-1-specific (siTSP-1) siRNA-transfected pVHL-positive and negative 786-O cells were added on top 
of type I collagen membranes and migrated cells were stained 16 hours later. Representative images of each 
condition are shown. Data are presented as mean ± SEM, n = 3. Statistical comparisons between different 
conditions were made using one-way ANOVA test followed by Bonferroni’s post-hoc test (*P < 0.05).
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the silencing of TSP-1 expression in cancer31. On the other hand, DNA methylation on TSP-1 CpG islands was 
found in approximately a 15% of cases in a cohort of clear cell RCC53. However, our results showed no changes 
at the transcriptional level and therefore this mechanism would not explain the decrease of TSP-1 levels in our 
RCC cell lines.
Tumour cells may bypass the effects of angiogenic inhibitors either by decreasing the expression of these 
factors themselves or by increasing the expression of pro-angiogenic factors. TSP-1 supports normal kidney angi-
ostasis, and its loss contributes to the RCC angiogenic phenotype (our current results and results by others)45–47. 
Although the mechanism by which TSP-1 is regulated in ccRCC cells remains elusive, our results clearly con-
tribute to the knowledge of ccRCC, and demonstrate that pVHL loss in these tumours affects their behaviour by 
modulating TSP-1 expression levels and this may partially explain pVHL anti-tumour activities. Additionally, 
we demonstrate that pVHL-mediated regulation of TSP-1 is a HIF-independent event. Further studies aiming 
at elucidating the regulation of angiogenesis inhibitors by pVHL will be beneficial for the development of new 
anti-angiogenic and anti-tumour therapies for ccRCC.
Methods
cell culture. Renal carcinoma cell line 786-O (CRL-1932) was obtained from the American Type Culture 
Collection (ATCC: Rockville, MD, USA), and RCC4 and RCC10 cell lines were kindly provided by Dr. W. 
Kaelin (Dana-Farber Cancer Institute, Boston, MA). 786-O cells were cultured in RPMI 1640 medium with 
GLUTAMAX-I whereas RCC4 and RCC10 were cultured in DMEM, both supplemented with 10% fetal bovine 
serum (FBS), 100 units/mL penicillin and 100 μg/mL streptomycin and maintained at 37 °C in a humidified 
atmosphere of 5% CO2. For hypoxia experiments, cells were incubated at 37 °C in an Invivo2 400 hypoxia worksta-
tion (Ruskinn Technology, West Yorkshire) in the presence of 5% CO2 and 1% oxygen for 24 h.
Retroviral transduction. 786-O, RCC4 and RCC10 cells stably expressing pVHL were generated as previ-
ously described54,55, by retroviral transduction with pRc/CMV or HA-VHL-pRc/CMV vectors, in the text named 
as pRV or pRV-VHL respectively, provided by Dr. W. Kaelin through Addgene (plasmids #20814 and 19999, 
respectively). Packaging 293-T cells were grown to 80–90% confluence in 10 cm culture plates. Fresh media 
without antibiotics was added and mixed with Optimem (1.5 mL/plate), Lipofectamine 2000 (Invitrogen) and 
the mix of vectors (10 μg of GAG-POL expression vector, 6.5 μg of ENV vector and 8.75 μg of the pRc/CMV 
or HA-VHL-pRc/CMV vectors). Media was changed after 4–6 h and cells cultured for 48 h. After that time cell 
media was filtered and mixed with equal volume of fresh medium. Diluted viral supernatants were then added 
(3 mL/plate) to the cells (786-O, RCC4 and RCC10 pVHL-negative clones) and incubated overnight at 37 °C. The 
transduction process was repeated two more times and stable clones were maintained in RPMI 1640 medium 
with GLUTAMAX-I supplemented with 10% FBS, 100 units/mL penicillin, 100 μg/mL streptomycin and 1 mg/
ml G418 (Invivogen, San Diego, CA). Additionally, we used 786-O expressing the naturally occurring type 2 C 
pVHL mutant L188V, or type 2 A pVHL mutant Y112H, that affect its alpha (L188V) or beta domain (Y112H). 
These mutants were kindly provided by Dr. Michael Ohh (University of Toronto, Canada). Furthermore, to 
assess the role of HIF in the regulation of TSP-1, retroviral vectors encoding the constitutively active mutated 
form of HIF-2α [HIF-2α P405A;P531A (P-A)2], a mutant lacking transcriptional activity [HIF-2α (P-A)2] 
P405A;P531A;bHLH] or the empty vector pBabe were used56.
truncated pVHL-mutant generation. Truncated pVHL-forms (1–161, 1–164 and 1–171) were gener-
ated by PCR using specific primers for each mutant (Table 1) and human cDNA as template. PCR products 
were extracted and purified from agarose gels using NucleoSpin gel clean-up kit (Macherey-Nagel) and each 
fragment was cloned into TOPO Pcr2.1 vector to transform Stbl3 bacteria (Thermo Fisher). Plasmid DNA from 
ampicillin-resistant clones was extracted with QIAprep Spin Miniprep Kit (QIAGEN) to confirm insert presence 
by Sanger sequencing (Secugen S.L.). Recombinant DNA was then purified using NucleoBond ® Xtra Maxi Plus 
(Macherey-Nagel) and amplified fragments were cloned into pLVX lentiviral expression vectors. Lentivirus were 
produced following a protocol similar to the one used for retroviral transduction. Briefly, packaging 293-T cells 
were grown to 50–60% confluence in 60 mm culture plates and co-transfected with the following mix of vectors: 
12.08 μg of pLVX expression vector, 9.17 μg of psPAX2 vector and 3.67 μg of pVSVg vector. Lentivirus-containing 
supernatants were collected and added to RCC4 pVHL-negative cells. Stable pVHL-mutants were maintained 
in RPMI 1640 medium with GLUTAMAX-I supplemented with 10% FBS, penicillin/streptomycin and 1 μg/mL 
puromycin (Thermo Fisher Scientific).
Real time pcR analysis. Quantitative RNA analysis was performed by real time PCR as previously 
described42. Changes in the TSP-1, VHL, VEGF, TP53, CDKN1A, MYC mRNA levels were analysed, using HPRT 
as housekeeping gene. Cells were grown to 95% confluence in 60-mm culture dishes and total cellular RNA was 
isolated using the Ultraspec RNA Isolation System (Biotecx Laboratories, Houston, TX). Total RNA (1 μg/sam-
ple) was reverse-transcribed to cDNA (Improm II RT, Promega, Madison, WI) in a final volume of 20 μL. For 
pVHL 
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quantitative PCR, 1 μL of cDNA was amplified with the specific primer pairs depicted in Table 2 and the following 
temperature cycles: 10 min initial denaturation at 95 °C, then 15 s denaturing at 95 °C, 1 min annealing at 60 °C 
and extended for 40 cycles. Following 40 cycles of DNA amplification, melting curves were performed at 95 °C for 
15 s, 60 °C for 1 min and 95 °C for 15 s.
conditioned media preparation. For the detection of secreted TSP-1, cells were cultured for 48 hours in 
DMEM depleted of FBS. Afterwards, conditioned media were collected and complete, EDTA-free, protease inhib-
itors (Roche, Indianapolis, IN) were added. To discard cell debris, samples were centrifuged (335 g for 5 minutes), 
50-fold concentrated and dialyzed to PBS using Amicon Ultra-15, 100 kDa membranes.
Western-blot analysis. Cells were grown to 95% confluence in 60-mm culture dishes and cell lysates 
were prepared in reducing 2X Laemmli buffer, boiled at 95 °C for 10 minutes, electrophoretically separated by 
SDS-PAGE and transferred onto 0.45-µm nitrocellulose membranes (GE Healthcare Life Sciences). Blots were 
incubated with 5% non-fat dry milk in TBS – 0.1% TweenTM 20 for 30 minutes at room temperature. Afterwards, 
blots were probed overnight at 4°C with the following primary antibodies: monoclonal anti-TSP-1 antibody 
Ab-11 (clones D4.6, AG.1, MBC 200.1, Neomarkers Lab Vision), monoclonal anti-pVHL antibody (clone VHL40, 
Santa Cruz), monoclonal anti-HIF-1α antibody (clone 241809, R&D Systems), polyclonal anti-HIF-2α antibody 
(Santa Cruz), monoclonal anti p53 antibody (clone DO-1, Santa Cruz), monoclonal anti-myc antibody (clone 
Y69, abcam) and monoclonal anti-p21 antibody (clone SX118, BD) and monoclonal anti-tubulin antibody (clone 
DM1A, Sigma). Anti-mouse (Dako) or anti-rabbit (GE Healthcare) HRP-conjugated secondary antibodies were 
added for 1 hour at room temperature and protein signal was then visualized using Immun-Star WesternCTM kit 
(BioRad).
siRnA transfection. Control small interfering RNA (scr) or specific siRNA directed to human TSP-1, 
HIF-1α, HIF-2α or pVHL (Santa Cruz) were transfected with Lipofectamine 2000 (Invitrogen) according to the 
manufacturer´s instruction. Three days after transfection, cells were used for the experiments.
protein immunoprecipitation. Cells were grown on 150-mm culture plates and lysates were prepared 
in RIPA buffer (150 mM NaCl, 10 mM Tris HCl, 1% SDS, 1% nonidet P-40, 1% sodium deoxycholate, pH 7.4) 
with protease and phosphatase inhibitors (Roche). For protein immunoprecipitation, 500 µg of total lysate were 
pre-cleared with 30 μL of 50% protein G (GE Healthcare, Pittsburgh, PA) in RIPA buffer for 30 minutes. After that, 
samples were centrifuged (380 g for 3 minutes) and supernatants were incubated at 4 °C for 1 hour with a mixture 
of protein G and non-specific IgG (Santa Cruz). Samples were again centrifuged (380 g for 3 minutes) and pellets 
were used as negative control for IP analysis. Conversely, supernatants were incubated with anti-pVHL or TSP-1 
antibodies at a final concentration of 1 μL per 100 μg of total protein at 4 °C for 16 hours. Finally, 30 μL of protein 
G were added and samples were again centrifuged (380 g for 3 minutes), discarding the supernatant. Pellets were 
rinsed with RIPA buffer and solubilized in reducing 2X Laemmli buffer for immunoblotting.
Immunofluorescence microscopy. Cells were seeded onto fibronectin coated 13-mm glass coverslips 
(5 μg/mL fibronectin) and then incubated for 24 h. Afterwards cells were fixed with 4% paraformaldehyde in PBS 
and permeabilized with 0.5% Triton in PBS with 1% BSA, 100 μg/mL gammaglobulin and 0.05% sodium azide. 
Cells were blocked for 30 min with 5% BSA in PBS with 100 μg/mL gammaglobulin and 0.05% sodium azide and 
stained with primary antibodies against β-catenin (BD Transduction Laboratories) or zonulin (ZO)-1 (Thermo 
Fisher Scientific) followed by Alexa Fluor 488 or 568-labeled secondary antibodies (Life Technologies). Cells were 
mounted in Prolong Gold (Invitrogen) and imaged with a Leica DMR 020–525.024 fluorescence microscope and 
Leica immersion objective HCX PL APO 40×/1.25–0.75. Images were collected using Leica TCS software.
cell migration and invasion assays. Migration experiments were performed with pVHL positive and 
negative cells or with cells transfected with a siRNA control or specific siRNA to TSP-1. Cells were plated onto 
a 24-well tissue culture plate (15 × 104 cells/well) and cultured in DMEM containing 5% (v/v) FBS at 37 °C. 
Experimental wounds were made with a P200 pipette tip across the central line of the culture plate. Number of 
migrated cells to the wounded area was determined by phase-contrast microscopy with a Nikon Eclipse TS100 
inverted microscope using a Nikon air objective Plan 4×/0.13 and NIS-Elements software, acquiring repre-
sentative images at representative areas of every experimental condition at time 0 h and after 16 h in culture. 
Cell migration and invasion were also evaluated in Transwell® filters (6.5-mm diameter, 8 μm pore size, Costar, 
Corning, NY). RCC cells serum starved for 24 h were seeded on top of the transwells (20 × 103 cells/well in 160 μl 








Table 2. List of the primer pairs used for gene expression analysis by real-time PCR.
1 1Scientific RepoRtS |         (2020) 10:1175  | https://doi.org/10.1038/s41598-020-58137-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
RPMI without FBS) and allowed to migrate overnight at 37 °C towards a lower chamber containing RPMI 10% 
FBS medium or without FBS as a negative control. Non-migrated cells in the upper surface of the membrane were 
gently removed with Q-tips and cells on the lower surface were fixed and stained with Diff-Quick (International 
Reagent, Kobe, Japan) and counted under the microscope with a Nikon air objective LWD 20×/0.40. Average of 
three different random fields per condition was calculated.
Statistical analysis. All data are presented as mean ± SEM. Two-tailed one-sample t-test was used to com-
pare two groups, and one-way ANOVA test followed by Bonferroni’s or linear trend post-hoc tests were used when 
comparing three or more groups, according with the conditions of normality and homoscedasticity. Shapiro–
Wilk and Brown–Forsythe tests were performed to analyse these conditions. P-values and P-trends < 0.05 were 
considered significant. All the statistical analyses were performed with GraphPad Prism 7.0a software (San Diego, 
CA, USA).
Data availability
The datasets generated and/or analysed during the current study are available from the corresponding author on 
reasonable request.
Received: 24 September 2019; Accepted: 7 January 2020;
Published: xx xx xxxx
References
 1. Kaelin, W. G. Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 13, 680s–684s, 
https://doi.org/10.1158/1078-0432.CCR-06-1865 (2007).
 2. Kaelin, W. G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2, 673–682 (2002).
 3. Latif, F. et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Sci. 260, 1317–1320 (1993).
 4. Clifford, S. C., Prowse, A. H., Affara, N. A., Buys, C. H. & Maher, E. R. Inactivation of the von Hippel-Lindau (VHL) tumour 
suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway 
in clear cell renal tumourigenesis. Genes Chromosomes Cancer 22, 200–209, https://doi.org/10.1002/(sici)1098-
2264(199807)22:3%3C200::aid-gcc5%3E3.0.co;2-# (1998).
 5. Kim, W. Y. & Kaelin, W. G. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22, 4991–5004, https://doi.org/10.1200/
JCO.2004.05.061 (2004).
 6. Rankin, E. B., Tomaszewski, J. E. & Haase, V. H. Renal cyst development in mice with conditional inactivation of the von Hippel-
Lindau tumor suppressor. Cancer Res. 66, 2576–2583 (2006).
 7. Zimmer, M., Doucette, D., Siddiqui, N. & Iliopoulos, O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression 
of VHL-/- tumors. Mol. Cancer Res. 2, 89–95 (2004).
 8. Iwai, K. et al. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc. 
Natl Acad. Sci. USA 96, 12436–12441 (1999).
 9. Lisztwan, J., Imbert, G., Wirbelauer, C., Gstaiger, M. & Krek, W. The von Hippel-Lindau tumor suppressor protein is a component 
of an E3 ubiquitin-protein ligase activity. Genes. Dev. 13, 1822–1833 (1999).
 10. Ivan, M. et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 
464–468 (2001).
 11. Jaakkola, P. et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. 
Science 292, 468–472 (2001).
 12. Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nat. 
399, 271–275 (1999).
 13. Maher, E. R. & Kaelin, W. G. Jr. Von Hippel-Lindau disease. Med. 76, 381–391 (1997).
 14. Guo, J. et al. pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. Sci. 353, 929–932, https://doi.
org/10.1126/science.aad5755 (2016).
 15. Calzada, M. J. Von Hippel-Lindau syndrome: molecular mechanisms of the disease. Clin. Transl. Oncol. 12, 160–165, https://doi.
org/10.1007/s12094-010-0485-9 (2010).
 16. Calzada, M. J. et al. Von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer 
cells through hypoxia-inducible factor-independent mechanisms. Cancer Res. 66, 1553–1560 (2006).
 17. Kurban, G., Hudon, V., Duplan, E., Ohh, M. & Pause, A. Characterization of a von Hippel Lindau pathway involved in extracellular 
matrix remodeling, cell invasion, and angiogenesis. Cancer Res. 66, 1313–1319 (2006).
 18. Bornstein, P. Thrombospondins as matricellular modulators of cell function. J. Clin. Invest. 107, 929–934, https://doi.org/10.1172/
JCI12749 (2001).
 19. Lawler, J. The functions of thrombospondin-1 and-2. Curr. Opin. Cell Biol. 12, 634–640, https://doi.org/10.1016/s0955-
0674(00)00143-5 (2000).
 20. Good, D. J. et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable 
from a fragment of thrombospondin. Proc. Natl Acad. Sci. USA 87, 6624–6628 (1990).
 21. Taraboletti, G., Roberts, D., Liotta, L. A. & Giavazzi, R. Platelet thrombospondin modulates endothelial cell adhesion, motility, and 
growth: a potential angiogenesis regulatory factor. J. Cell Biol. 111, 765–772 (1990).
 22. Lawler, J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J. Cell Mol. Med. 6, 1–12, https://doi.
org/10.1111/j.1582-4934.2002.tb00307.x (2002).
 23. Volpert, O. V. Modulation of endothelial cell survival by an inhibitor of angiogenesis thrombospondin-1: a dynamic balance. Cancer 
Metastasis Rev. 19, 87–92 (2000).
 24. Jimenez, B. et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med. 6, 41–48 
(2000).
 25. Bornstein, P. Thrombospondins: structure and regulation of expression. FASEB J. 6, 3290–3299 (1992).
 26. Campbell, S. C., Volpert, O. V., Ivanovich, M. & Bouck, N. P. Molecular mediators of angiogenesis in bladder cancer. Cancer Res. 58, 
1298–1304 (1998).
 27. Isenberg, J. S., Martin-Manso, G., Maxhimer, J. B. & Roberts, D. D. Regulation of nitric oxide signalling by thrombospondin 1: 
implications for anti-angiogenic therapies. Nat. Rev. Cancer 9, 182–194, https://doi.org/10.1038/nrc2561 (2009).
 28. Bornstein, P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J. Cell Biol. 130, 503–506 
(1995).
 29. Lahav, J. The functions of thrombospondin and its involvement in physiology and pathophysiology. Biochim. Biophys. Acta 1182, 
1–14, https://doi.org/10.1016/0925-4439(93)90146-r (1993).
1 2Scientific RepoRtS |         (2020) 10:1175  | https://doi.org/10.1038/s41598-020-58137-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
 30. Kazerounian, S., Yee, K. O. & Lawler, J. Thrombospondins in cancer. Cell Mol. Life Sci. 65, 700–712, https://doi.org/10.1007/s00018-
007-7486-z (2008).
 31. Li, Q., Ahuja, N., Burger, P. C. & Issa, J. P. Methylation and silencing of the Thrombospondin-1 promoter in human cancer. Oncogene 
18, 3284–3289, https://doi.org/10.1038/sj.onc.1202663 (1999).
 32. Ohh, M. et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin 
matrix. Mol. Cell 1, 959–968 (1998).
 33. Esteban-Barragan, M. A. et al. Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar 
adhesions. Cancer Res. 62, 2929–2936 (2002).
 34. Feijoo-Cuaresma, M. et al. Inadequate activation of the GTPase RhoA contributes to the lack of fibronectin matrix assembly in von 
Hippel-Lindau protein-defective renal cancer cells. J. Biol. Chem. 283, 24982–24990, https://doi.org/10.1074/jbc.M709390200 
(2008).
 35. Grosfeld, A. et al. Interaction of hydroxylated collagen IV with the von hippel-lindau tumor suppressor. J Biol Chem. 282, 13264-
13269. Epub 12007 Mar 13265 (2007).
 36. Kurban, G. et al. Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with 
hydroxylated collagen IV alpha 2. Oncogene 13, 13 (2007).
 37. Guo, Y., Schoell, M. C. & Freeman, R. S. The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through 
stabilization of BIM(EL). Oncogene 28, 1864–1874, https://doi.org/10.1038/onc.2009.35 (2009).
 38. Zhou, M. I., Wang, H., Foy, R. L., Ross, J. J. & Cohen, H. T. Tumor suppressor von Hippel-Lindau (VHL) stabilization of Jade-1 
protein occurs through plant homeodomains and is VHL mutation dependent. Cancer Res. 64, 1278–1286 (2004).
 39. Ohh, M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau 
protein. Nat. Cell Biol. 2, 423–427 (2000).
 40. Hoffman, M. A. et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. 
Hum. Mol. Genet. 10, 1019–1027 (2001).
 41. Ohh, M. & Kaelin, W. G. Jr. The von Hippel-Lindau tumour suppressor protein: new perspectives. Mol. Med. Today 5, 257–263 
(1999).
 42. Bienes-Martinez, R. et al. Autocrine stimulation of clear-cell renal carcinoma cell migration in hypoxia via HIF-independent 
suppression of thrombospondin-1. Sci. Rep. 2, 788, https://doi.org/10.1038/srep00788 (2012).
 43. Deniz, B. et al. Treatment sequences for advanced renal cell carcinoma: A health economic assessment. PLoS One 14, e0215761, 
https://doi.org/10.1371/journal.pone.0215761 (2019).
 44. Ndiaye, P. D. et al. VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness. Theranostics 9, 661–675, https://doi.
org/10.7150/thno.27794 (2019).
 45. Zubac, D. P. et al. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, 
cell proliferation and cancer specific survival. J. Urol. 182, 2144–2149, https://doi.org/10.1016/j.juro.2009.07.015 (2009).
 46. Veliceasa, D. et al. Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell 
carcinoma. FEBS J. 274, 6365–6377, https://doi.org/10.1111/j.1742-4658.2007.06159.x (2007).
 47. Bussolati, B., Assenzio, B., Deregibus, M. C. & Camussi, G. The proangiogenic phenotype of human tumor-derived endothelial cells 
depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway. J. Mol. Med. 84, 852–863, https://
doi.org/10.1007/s00109-006-0075-z (2006).
 48. Roe, J. S. et al. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol. Cell 22, 395–405 (2006).
 49. Wen, S. et al. PTEN controls tumor-induced angiogenesis. Proc. Natl Acad. Sci. USA 98, 4622–4627, https://doi.org/10.1073/
pnas.081063798 (2001).
 50. Dameron, K. M., Volpert, O. V., Tainsky, M. A. & Bouck, N. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the 
production of thrombospondin. Cold Spring Harb. Symp. Quant. Biol. 59, 483–489 (1994).
 51. Volpert, O. V. et al. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell 2, 473–483 
(2002).
 52. Stickle, N. H. et al. Expression of p53 in renal carcinoma cells is independent of pVHL. Mutat. Res. 578, 23–32, https://doi.
org/10.1016/j.mrfmmm.2005.02.016 (2005).
 53. Arai, E. et al. Genetic clustering of clear cell renal cell carcinoma based on array-comparative genomic hybridization: its association 
with DNA methylation alteration and patient outcome. Clin. Cancer Res. 14, 5531–5539, https://doi.org/10.1158/1078-0432.CCR-
08-0443 (2008).
 54. Fernandez-Sanchez, R. et al. AG490 promotes HIF-1alpha accumulation by inhibiting its hydroxylation. Curr. Med. Chem. 19, 
4014–4023, https://doi.org/10.2174/092986712802002554 (2012).
 55. Labrousse-Arias, D. et al. VHL promotes immune response against renal cell carcinoma via NF-kappaB-dependent regulation of 
VCAM-1. J. Cell Biol. 216, 835–847, https://doi.org/10.1083/jcb.201608024 (2017).
 56. Kondo, K., Klco, J., Nakamura, E., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF is necessary for tumor suppression by the 
von Hippel-Lindau protein. Cancer Cell 1, 237–246 (2002).
Acknowledgements
This work was supported by grants from the Spanish Government (co-funded by European Regional 
Development Fund, ERDF/FEDER); PI16/02166 and 2017/EEUU/03 to MJC; Red Temática de Excelencia en 
Investigación en Hipoxia (SAF 2017-90794-REDT) to MJC. We also thank Dr. Manuel Gómez Gutierrez for 
critical reading and editing this manuscript.
Author contributions
M.J.C. and R.B. conceived and designed research; J.S.M., R.B., D.L., E.F.Y. and A.O. conducted experiments, 
acquired data and prepared figures; J.S.M. and R.B. analysed data; J.S.M., R.B. and M.J.C. interpreted results of 
experiments. M.J.C. and J.S.M. drafted the manuscript. All authors approved the final version of manuscript.
competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-58137-w.
Correspondence and requests for materials should be addressed to M.J.C.
Reprints and permissions information is available at www.nature.com/reprints.
13Scientific RepoRtS |         (2020) 10:1175  | https://doi.org/10.1038/s41598-020-58137-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
